Professor of Medicine
McMaster University
McMaster Unviersity
Dr. Shamir Mehta is the Douglas A. Holder Endowed Chair and Professor of Medicine at McMaster University. He directs the Royal College fellowship in interventional cardiology and leads the mitral and tricuspid valve transcatheter edge-to-edge repair programs at Hamilton Health Sciences and McMaster University. He completed medical school and post graduate training at the University of Toronto, followed by a research fellowship at McMaster University where he was supported by a Canadian Institutes of Health Research New Investigator Award. He is a Senior Scientist at the Population Health Research Institute where he leads landmark clinical trials evaluating revascularization strategies and novel pharmacologic interventions in patients with acute coronary syndromes. Dr. Mehta is currently the Principal Investigator of the COMPLETE-2 trial, a 5,100-patient multinational trial evaluating the role of physiology-guided versus angiography-guided PCI strategies to treat non-culprit lesions in patients with ACS and multivessel coronary artery disease, including a large-scale intracoronary imaging study using optical coherence tomography to predict cardiovascular events. He is a member of the executive committee of the Librexia ACS trial evaluating a novel Factor XIa inhibitor in ACS and he is a steering committee member of OCEAN(a) evaluating targeted lowering of lipoprotein(a) with a novel small interfering RNA after ACS or PCI.
Dr. Mehta has published hundreds of research articles and holds millions of dollars in peer review research grants from CIHR and industry. In 2022, he was honoured with the Canadian Cardiovascular Society’s Research Achievement Award.
Disclosure(s): Abbott: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Amgen: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Bristol-Myers Squibb: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Noronordisk: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Novartis: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)
Thursday, October 24, 2024
1:44 PM – 1:51 PM PT
213 - INNOVATION PLENARY: HOW CARDIOLOGY'S FUTURE UNFOLDS
Friday, October 25, 2024
8:30 AM – 9:30 AM PT